研究领域：

研究领域为肿瘤靶向治疗，主要包括单克隆抗体和纳米药物的肿瘤靶向治疗及分子机制研究，以及光动力治疗药物研发。近期研究的肿瘤相关靶标为NRP-1和GIPC蛋白，其中NRP-1是一个细胞膜表面糖蛋白，在肿瘤和肿瘤新生血管中高表达，与肿瘤的生长、侵袭、转移密切相关，它是一个多功能细胞表面受体，参与调节VEGF、Sema、EGF、PDGF和FN等细胞因子的信号通路，与肿瘤的发生发展以及患者的预后密切相关，被认为是一个很有前景的癌症治疗靶点。

学习经历：

1993~1998 福建医科大学预防医学专业  医学学士；

1998~2001 福建医科大学药理学专业   医学硕士；

2006~2013 厦门大学高分子化学与物理专业  理学博士；

2016~2017 美国Mayo Clinic   访问学者/博士后。

工作经历：

2001~2003厦门大学抗癌研究中心 助教；

2004~2014太阳成集团tyc234cc抗癌研究中心 助理教授；

2014~至今太阳成集团tyc234cc抗癌研究中心 副教授。

代表性成果：

1. Yang Li¹, Jinyan Lin¹, Jinyuan Ma, Liang Song, Huirong Lin, Bowen Tang, Dengyue Chen, Guanghao Su, Shefang Ye, Xuan Zhu, Fanghong Luo*, and Zhenqing Hou*, Methotrexate –Camptothecin Prodrug Nanoassemblies as a Versatile Nanoplatform for Biomodal Imaging-Guided Self-Active Targeted and Synergistic Chemotherapy, ACS Appl. Mater. Interfaces, 2017, 9 (40), pp 34650–34665 (Corresponding author).

2. Drinane MC¹, Yaqoob U¹, Yu H¹, Luo F¹,Greuter T, Arab JP, Kostallari E, Verma VK, Maiers J, De Assuncao TM, Simons M, Mukhopadhyay D, Kisseleva T, Brenner DA, Urrutia R, Lomberk G, Gao Y, Ligresti G, Tschumperlin DJ, Revzin A, Cao S*, Shah VH*，Synectin promotes fibrogenesis by regulating PDGFR isoforms through distinct mechanisms. JCI Insight. 2017 Dec 21;2(24). pii: 92821. (Co-first author)

3. Hou, ZQ¹,Lin, JY ,Li, YX,Guo, FQ,Yu, F,Wu, HJ,Fan, ZX,Zhi, LL,Luo, FH*.Validation of a dual role of methotrexate-based chitosan nanoparticles in vivo, RSC ADVANCES,2015(5): 52:41393-41400 (Corresponding author).

4. Lin, JY¹, Li, YX¹ , Li, Y¹, Cui, F , Yu, F , Wu, HJ, Xie, LY ,Luo, FH* , Hou, ZQ*, Lin, CJ.Self-targeted, bacillus-shaped, and controlled-release methotrexate prodrug polymeric nanoparticles for intratumoral administration with improved therapeutic efficacy in tumor-bearing mice，JOURNAL OF MATERIALS CHEMISTRY B.2015,3(39): 7707-7717 (Corresponding author).

5. Fanghong Luo¹, Yang Li¹, Mengmeng Jia, Fei Cui, Hongjie Wu, Fei Yu, Jinyan Lin, Xiangrui Yang,Zhenqing Hou* and Qiqing Zhang*.Validation of a Janus role of methotrexate-based PEGylated chitosan nanoparticles in vitro,Nanoscale Research Letters 2014, 9(7):363-375

6. Fanwei Zeng¹, Fanghong Luo¹, Sha Lv, Haipeng Zhang, Chang Cao,Xiaoli Chen, Shengyu Wang, Zhe Li, Xianjiang Wang, Xiaofeng Dou,Yujuan Dai,c, Mingjun He, Yafei Zhang, Haiyan Lv, Jianghua Yan* and Yuqiang Chen*,A monoclonal antibody targeting neuropilin-1 inhibits the adhesion of breast cancer cell MCF7 to fibronectin by suppressing FAK/p130cas signaling pathway，Anticancer Drugs. 2014 Jul;25(6)663-72 (Co-first author)

7. Chen L¹, Miao W¹, Tang X, Zhang H, Wang S, Luo F*, Yan J. Inhibitory effect of neuropilin-1 monoclonal antibody (NRP-1 MAb) on glioma tumor in mice. J Biomed Nanotechnol. 2013 Apr;9(4):551-8 (Corresponding author).  

8. Xiaoli Chen¹, Haiyan Lv¹, Min Ye, Shengyu Wang, Erru Ni, Fanwei Zeng, Chang Cao, Fanghong Luo*, Jianghua Yan*，Novel superparamagnetic iron oxide nanoparticles for tumor embolization application: Preparation, characterization and double targeting，International Journal of Pharmaceutics. 2012，426:248-255 (Corresponding author)

9. Fanwei Zeng¹, Erru Ni¹, Shengyu Wang, Sha Lv, Chang Cao, Haipeng Zhang, Haiyan Lv, Xiaoli Chen, Jianghua Yan*, and Fanghong Luo*，Monoclonal Antibody against Catalytic Domain of PTP1B，Hybridoma，2012，31（3）: 209-213 (Corresponding author)

10. Xiang Li¹, Fanghong luo¹, Shengyu Wang , Erru Ni，Xiaoyong Tang，Haiyan Lv，Xiaoli Chen，Lukui Chen，and Jianghua Yan*,M A onoclonal Antibody Against NRP1 b1b2，Hybridoma，2011,(30): 369-373 (Co-first author).

主持过的重要课题：

1. NRP-1介导PI3K/AKT信号通路调控乳腺癌淋巴管生成和转移的机制研究，国家自然科学基金面上项目，2015-2018，项目负责人

2. GIPC促进肝癌细胞黏附迁移及其作用机制研究,福建省科技计划项目，2017-2019，项目负责人 

3. 抗NRP-1功能性抗体的研制及抗肿瘤作用研究，厦门市科技计划项目，2015-2017，项目负责人

4. 抗SEMA3FC单克隆抗体制备及ELISA检测方法建立，福建省科技计划项目，2014-2016，项目负责人

5. NRP-1单抗介导智能纳米载药系统研制及靶向治疗肝癌研究，福建省自然科学基金，2013-2015，项目负责人

6. 肿瘤靶向性新型紫杉醇纳米制剂的研制及其应用，福建省科技计划项目，2009-2011，项目负责人

已申请的专利：

1. 颜江华，王生育，罗芳洪，吴婷，王勇军，一种葡聚糖的夹心酶联免疫吸附测定方法，申请号，CN201510513781.9，2015-08-20，专利号，CN105137084B，2016-09-28

2. 颜江华，王生育，罗芳洪，吴婷，倪二茹，王勇军，抗人神经纤毛蛋白1的单域抗体及其制备方法，申请号，CN201510757571.4，2015-11-10，公告号，CN105237637A

所有论文列表：

1. Yang Li¹, Jinyan Lin¹, Jinyuan Ma, Liang Song, Huirong Lin, Bowen Tang, Dengyue Chen, Guanghao Su, Shefang Ye, Xuan Zhu, Fanghong Luo*, and Zhenqing Hou*, Methotrexate –Camptothecin Prodrug Nanoassemblies as a Versatile Nanoplatform for Biomodal Imaging-Guided Self-Active Targeted and Synergistic Chemotherapy, ACS Appl. Mater. Interfaces, 2017, 9 (40), pp 34650–34665 (Corresponding author). https://pubs.acs.org/doi/10.1021/acsami.7b10027

2. Drinane MC¹, Yaqoob U¹, Yu H¹, Luo F¹,Greuter T, Arab JP, Kostallari E, Verma VK, Maiers J, De Assuncao TM, Simons M, Mukhopadhyay D, Kisseleva T, Brenner DA, Urrutia R, Lomberk G, Gao Y, Ligresti G, Tschumperlin DJ, Revzin A, Cao S*, Shah VH*，Synectin promotes fibrogenesis by regulating PDGFR isoforms through distinct mechanisms. JCI Insight. 2017 Dec 21;2(24). pii: 92821. (Co-first author)

https://insight.jci.org/articles/view/92821

3. Hou, ZQ¹,Lin, JY ,Li, YX,Guo, FQ,Yu, F,Wu, HJ,Fan, ZX,Zhi, LL,Luo, FH*.Validation of a dual role of methotrexate-based chitosan nanoparticles in vivo, RSC ADVANCES,2015(5): 52:41393-41400 (Corresponding author).

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4118220/

4. Lin, JY¹, Li, YX¹ , Li, Y¹, Cui, F , Yu, F , Wu, HJ, Xie, LY ,Luo, FH* , Hou, ZQ*, Lin, CJ.Self-targeted, bacillus-shaped, and controlled-release methotrexate prodrug polymeric nanoparticles for intratumoral administration with improved therapeutic efficacy in tumor-bearing mice，JOURNAL OF MATERIALS CHEMISTRY B.2015,3(39): 7707-7717 (Corresponding author).

http://apps.webofknowledge.com/full_record.do?product=WOS&search_mode=GeneralSearch&qid=2&SID=7EIeorIzVz3bvF6hiIM&page=1&doc=5

5. Fanghong Luo¹, Yang Li¹, Mengmeng Jia, Fei Cui, Hongjie Wu, Fei Yu, Jinyan Lin, Xiangrui Yang,Zhenqing Hou* and Qiqing Zhang*.Validation of a Janus role of methotrexate-based PEGylated chitosan nanoparticles in vitro,Nanoscale Research Letters 2014, 9(7):363-375

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4118220/

6. Fanwei Zeng¹, Fanghong Luo¹, Sha Lv, Haipeng Zhang, Chang Cao,Xiaoli Chen, Shengyu Wang, Zhe Li, Xianjiang Wang, Xiaofeng Dou,Yujuan Dai,c, Mingjun He, Yafei Zhang, Haiyan Lv, Jianghua Yan* and Yuqiang Chen*,A monoclonal antibody targeting neuropilin-1 inhibits the adhesion of breast cancer cell MCF7 to fibronectin by suppressing FAK/p130cas signaling pathway，Anticancer Drugs. 2014 Jul;25(6)663-72 (Co-first author)

https://insights.ovid.com/pubmed?pmid=24583771

7. Chen L¹, Miao W¹, Tang X, Zhang H, Wang S, Luo F*, Yan J. Inhibitory effect of neuropilin-1 monoclonal antibody (NRP-1 MAb) on glioma tumor in mice. J Biomed Nanotechnol. 2013 Apr;9(4):551-8 (Corresponding author).

https://www.ncbi.nlm.nih.gov/pubmed/23621013

8. Xiaoli Chen¹, Haiyan Lv¹, Min Ye, Shengyu Wang, Erru Ni, Fanwei Zeng, Chang Cao, Fanghong Luo*, Jianghua Yan*，Novel superparamagnetic iron oxide nanoparticles for tumor embolization application: Preparation, characterization and double targeting，International Journal of Pharmaceutics. 2012，426:248-255 (Corresponding author)

https://www.sciencedirect.com/science/article/pii/S037851731200097X?via%3Dihub

9. Fanwei Zeng¹, Erru Ni¹, Shengyu Wang, Sha Lv, Chang Cao, Haipeng Zhang, Haiyan Lv, Xiaoli Chen, Jianghua Yan*, and Fanghong Luo*，Monoclonal Antibody against Catalytic Domain of PTP1B，Hybridoma，2012，31（3）: 209-213 (Corresponding author)

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3385999/

10. Xiang Li¹, Fanghong luo¹, Shengyu Wang , Erru Ni，Xiaoyong Tang，Haiyan Lv，Xiaoli Chen，Lukui Chen，and Jianghua Yan*,M A onoclonal Antibody Against NRP1 b1b2，Hybridoma，2011,(30): 369-373 (Co-first author).

http://online.liebertpub.com/doi/abs/10.1089/hyb.2011.0012